Use of 3′-deoxy-3′-[18F]fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors

Yang, Young-Kyu; Ryu, Jin‐Sook; Kim, Seog-Young; Oh, Seung Jun; Im, Ki Chun; Lee, Heuiran; Lee, Sangwook; Cho, Kyung Ja; Cheon, Gi Jeong; Moon, Dae Hyuk

doi:10.1007/s00259-005-0011-4

Cited by 67 publications

(53 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Importantly, these reductions in FLT tumor uptake were not secondary to decreases in tumor volume, because early reduction in FLT uptake occurred during the first few days of cytostatic tumor growth. Similar findings were reported in other FLT-PET preclinical studies that used different anticancer therapies, including chemotherapy (15,16,19) and radiation (12,17). Our data lend further support to the literature showing the ability of FLT-PET to detect therapeutic alterations in tumor biology before changes in tumor size are clinically detectable.…”

Section: Discussionsupporting

confidence: 88%

“…Similarly, we showed early decreases in FLT tumor uptake that were more pronounced and specific for tumor proliferation than those of FDG. Furthermore, when normalizing FLT uptake to background (muscle) uptake as was done in other studies (12,18,19), FLT displayed a much greater T/M signal contrast than FDG. Our data provide additional evidence for the assertion that imaging tumor proliferation with [ 18 F]FLT is more suitable for monitoring treatment response than imaging tumor glucose metabolism.…”

Section: H]flt and [mentioning

confidence: 89%

See 1 more Smart Citation

Early Detection of Chemoradioresponse in Esophageal Carcinoma by 3′-Deoxy-3′-3H-Fluorothymidine Using Preclinical Tumor Models

Apisarnthanarax

Alauddin²,

Mourtada³

et al. 2006

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Early identification of esophageal cancer patients who are responding or resistant to combined chemoradiotherapy may lead to individualized therapeutic approaches and improved clinical outcomes. We assessed the ability of 3 ¶-deoxy-3 ¶- Conclusions: FLT-PET is suitable and more specific than FDG-PET for depicting early reductions in tumor proliferation that precede tumor size changes after chemoradiotherapy.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: H]flt and [mentioning

confidence: 89%

Early Detection of Chemoradioresponse in Esophageal Carcinoma by 3′-Deoxy-3′-3H-Fluorothymidine Using Preclinical Tumor Models

Apisarnthanarax

Alauddin²,

Mourtada³

et al. 2006

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…PET is currently relied on as a noninvasive technique for the detection of early-phase responses of tumor cells to therapy (e.g., chemotherapy and radiotherapy) (4,(13)(14)(15)(16)(17). L-11 C-MET and 18 F-FLT imaging has been reported to show more sensitivity and faster response to irradiation than does 18 F-FDG imaging (4,(13)(14)(15).…”

mentioning

confidence: 99%

Evaluation of d-¹⁸F-FMT, ¹⁸F-FDG, l-¹¹C-MET, and ¹⁸F-FLT for Monitoring the Response of Tumors to Radiotherapy in Mice

Murayama

Harada²,

Kakiuchi³

et al. 2009

J Nucl Med

View full text Add to dashboard Cite

“…The potential of 18 F-FLT PET/CT for early assessment of chemotherapy has been demonstrated in a variety of cancers (101)(102)(103). In the context of radiotherapy, 18 F-FLT PET/CT first proved its sensitivity to ionizing radiation in preclinical tumor models (104,105). After promising results from 18 F-FLT PET/CT-based assessments of radiation response in these models, an increasing number of studies have shown that decreased 18 F-FLT uptake early (as early as 5 d/ 10 Gy) in the course of radiotherapy or chemoradiotherapy is a strong indicator of long-term outcome in a large-animal preclinical model (106) and humans (107)(108)(109)(110) (Fig.…”

Section: Prognostic Role Of Molecular Imaging In Radiation Therapymentioning

confidence: 99%

Molecular Imaging to Plan Radiotherapy and Evaluate Its Efficacy

2015

View full text Add to dashboard Cite

Learning Objectives: On successful completion of this activity, participants should be able to describe (1) how to acquire high-quality molecular images for use in radiation therapy; (2) how molecular imaging can be used to plan radiotherapy and evaluate treatment efficacy; and (3) the limitations and challenges to widespread use of molecular imaging in radiation oncology.Financial Disclosure: The authors of this article have indicated no relevant relationships that could be perceived as a real or apparent conflict of interest. CME Credit: SNMMI is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians. SNMMI designates each JNM continuing education article for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only credit commensurate with the extent of their participation in the activity. For CE credit, SAM, and other credit types, participants can access this activity through the SNMMI website (http://www.snmmilearningcenter.org) through November 2018.Molecular imaging plays a central role in the management of radiation oncology patients. Specific uses of imaging, particularly to plan radiotherapy and assess its efficacy, require an additional level of reproducibility and image quality beyond what is required for diagnostic imaging. Specific requirements include proper patient preparation, adequate technologist training, careful imaging protocol design, reliable scanner technology, reproducible software algorithms, and reliable data analysis methods. As uncertainty in target definition is arguably the greatest challenge facing radiation oncology, the greatest impact that molecular imaging can have may be in the reduction of interobserver variability in target volume delineation and in providing greater conformity between target volume boundaries and true tumor boundaries. Several automatic and semiautomatic contouring methods based on molecular imaging are available but still need sufficient validation to be widely adopted. Biologically conformal radiotherapy (dose painting) based on molecular imaging-assessed tumor heterogeneity is being investigated, but many challenges remain to fully exploring its potential. Molecular imaging also plays increasingly important roles in both early (during treatment) and late (after treatment) response assessment as both a predictive and a prognostic tool. Because of potentially confounding effects of radiation-induced inflammation, treatment response assessment requires careful interpretation. Although molecular imaging is already strongly embedded in radiotherapy, the path to widespread and all-inclusive use is still long. The lack of solid clinical evidence is the main impediment to broader use. Recommendations for practicing physicians are still rather scarce. 18 F-FDG PET/CT remains the main molecular imaging modality in radiation oncology applications. Although other molecular imaging options (e.g., proliferation imaging) are becoming more common, their widespread use is limited ...

show abstract

Use of 3′-deoxy-3′-[18F]fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors

Abstract: Our finding that tumor uptake of FLT was reduced at 24 h after radiation treatment suggests that FLT PET may be a promising imaging modality for monitoring the early effects of radiation therapy.

Cited by 67 publications

References 35 publications

Early Detection of Chemoradioresponse in Esophageal Carcinoma by 3′-Deoxy-3′-3H-Fluorothymidine Using Preclinical Tumor Models

Early Detection of Chemoradioresponse in Esophageal Carcinoma by 3′-Deoxy-3′-3H-Fluorothymidine Using Preclinical Tumor Models

Evaluation of d-¹⁸F-FMT, ¹⁸F-FDG, l-¹¹C-MET, and ¹⁸F-FLT for Monitoring the Response of Tumors to Radiotherapy in Mice

Molecular Imaging to Plan Radiotherapy and Evaluate Its Efficacy

Contact Info

Product

Resources

About

Use of 3′-deoxy-3′-[18F]fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors

Abstract: Our finding that tumor uptake of FLT was reduced at 24 h after radiation treatment suggests that FLT PET may be a promising imaging modality for monitoring the early effects of radiation therapy.

Cited by 67 publications

References 35 publications

Early Detection of Chemoradioresponse in Esophageal Carcinoma by 3′-Deoxy-3′-3H-Fluorothymidine Using Preclinical Tumor Models

Early Detection of Chemoradioresponse in Esophageal Carcinoma by 3′-Deoxy-3′-3H-Fluorothymidine Using Preclinical Tumor Models

Evaluation of d-18F-FMT, 18F-FDG, l-11C-MET, and 18F-FLT for Monitoring the Response of Tumors to Radiotherapy in Mice

Molecular Imaging to Plan Radiotherapy and Evaluate Its Efficacy

Contact Info

Product

Resources

About

Evaluation of d-¹⁸F-FMT, ¹⁸F-FDG, l-¹¹C-MET, and ¹⁸F-FLT for Monitoring the Response of Tumors to Radiotherapy in Mice